MX2012003851A - Tratamiento de cánceres resistentes antagonistas notch1, mediante el uso de antagonistas notch3. - Google Patents
Tratamiento de cánceres resistentes antagonistas notch1, mediante el uso de antagonistas notch3.Info
- Publication number
- MX2012003851A MX2012003851A MX2012003851A MX2012003851A MX2012003851A MX 2012003851 A MX2012003851 A MX 2012003851A MX 2012003851 A MX2012003851 A MX 2012003851A MX 2012003851 A MX2012003851 A MX 2012003851A MX 2012003851 A MX2012003851 A MX 2012003851A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating cancer
- notch
- notch antagonists
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invención se refiere a métodos para el tratamiento del cáncer en general y leucemia en particular, utilizando antagonistas de Notch1 y Notch3 solos o en combinación. También se proporcionan composiciones y métodos para el tratamiento y diagnóstico de tipos de cáncer asociados a Notch.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24729809P | 2009-09-30 | 2009-09-30 | |
PCT/US2010/050610 WO2011041336A2 (en) | 2009-09-30 | 2010-09-29 | Methods of treating cancer using notch antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012003851A true MX2012003851A (es) | 2012-05-08 |
MX342250B MX342250B (es) | 2016-09-22 |
Family
ID=43127684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012003851A MX342250B (es) | 2009-09-30 | 2010-09-29 | Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3. |
Country Status (21)
Country | Link |
---|---|
US (1) | US9200071B2 (es) |
EP (1) | EP2483311B1 (es) |
JP (3) | JP6025563B2 (es) |
KR (1) | KR101782180B1 (es) |
CN (1) | CN102630229B (es) |
AU (1) | AU2010300747A1 (es) |
BR (1) | BR112012007252A2 (es) |
CA (1) | CA2775880A1 (es) |
CL (1) | CL2012000800A1 (es) |
CO (1) | CO6531430A2 (es) |
CR (1) | CR20120213A (es) |
EC (1) | ECSP12011858A (es) |
ES (1) | ES2580229T3 (es) |
HK (1) | HK1170505A1 (es) |
IL (1) | IL218662A0 (es) |
MA (1) | MA33973B1 (es) |
MX (1) | MX342250B (es) |
PE (1) | PE20120998A1 (es) |
RU (1) | RU2012117619A (es) |
WO (1) | WO2011041336A2 (es) |
ZA (1) | ZA201201984B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009539403A (ja) | 2006-06-13 | 2009-11-19 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断および処置するための組成物および方法 |
CA2676008A1 (en) | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
CN102112490B (zh) | 2008-07-08 | 2014-10-22 | 昂考梅德药品有限公司 | Notch1受体结合剂和其使用方法 |
CN102686610A (zh) | 2009-06-18 | 2012-09-19 | 辉瑞公司 | 抗刻缺蛋白-1抗体 |
MX346995B (es) | 2010-12-15 | 2017-04-06 | Wyeth Llc | Anticuerpos anti-notch1. |
TWI589590B (zh) * | 2012-11-07 | 2017-07-01 | 輝瑞股份有限公司 | 抗切口3(anti-notch3)抗體及抗體-藥物共軛體 |
PL2935330T3 (pl) * | 2012-12-19 | 2019-11-29 | Aveo Pharmaceuticals Inc | Przeciwciała przeciw notch3 |
EP3611189A1 (en) * | 2013-03-14 | 2020-02-19 | Novartis AG | Antibodies against notch 3 |
WO2014159242A1 (en) * | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
EP2971146A4 (en) * | 2013-03-15 | 2016-11-09 | Oncomed Pharm Inc | METHOD FOR THE TREATMENT OF PANCREATIC CANCER |
EP3024457A4 (en) | 2013-07-26 | 2017-06-28 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
AR099465A1 (es) * | 2014-02-12 | 2016-07-27 | Genentech Inc | Anticuerpos anti-jagged1 y métodos de uso |
CN106488775A (zh) | 2014-07-11 | 2017-03-08 | 基因泰克公司 | Notch途径抑制 |
CN105585636B (zh) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用 |
US11142573B2 (en) | 2016-04-29 | 2021-10-12 | Aveo Pharmaceuticals, Inc. | Anti-Notch3 antibody |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
MX2007008017A (es) | 2004-12-31 | 2007-09-12 | Genentech Inc | Polipeptidos que se ligan a br3 y usos de los mismos. |
AU2007309229B8 (en) | 2006-10-19 | 2013-05-09 | Genentech, Inc. | Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases |
TW200823293A (en) | 2006-10-19 | 2008-06-01 | Genentech Inc | Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease |
TWI419904B (zh) | 2006-12-18 | 2013-12-21 | Genentech Inc | 拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途 |
CA2676008A1 (en) * | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
WO2008108910A2 (en) * | 2007-03-05 | 2008-09-12 | Board Of Regents, The University Of Texas System | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
CN102112490B (zh) * | 2008-07-08 | 2014-10-22 | 昂考梅德药品有限公司 | Notch1受体结合剂和其使用方法 |
WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
CN102686610A (zh) * | 2009-06-18 | 2012-09-19 | 辉瑞公司 | 抗刻缺蛋白-1抗体 |
-
2010
- 2010-09-29 PE PE2012000413A patent/PE20120998A1/es not_active Application Discontinuation
- 2010-09-29 AU AU2010300747A patent/AU2010300747A1/en not_active Abandoned
- 2010-09-29 JP JP2012532248A patent/JP6025563B2/ja active Active
- 2010-09-29 KR KR1020127010886A patent/KR101782180B1/ko active IP Right Grant
- 2010-09-29 US US13/498,560 patent/US9200071B2/en active Active
- 2010-09-29 BR BR112012007252-8A patent/BR112012007252A2/pt not_active IP Right Cessation
- 2010-09-29 CA CA2775880A patent/CA2775880A1/en not_active Abandoned
- 2010-09-29 MX MX2012003851A patent/MX342250B/es active IP Right Grant
- 2010-09-29 MA MA34797A patent/MA33973B1/fr unknown
- 2010-09-29 RU RU2012117619/10A patent/RU2012117619A/ru not_active Application Discontinuation
- 2010-09-29 EP EP10762827.3A patent/EP2483311B1/en active Active
- 2010-09-29 ES ES10762827.3T patent/ES2580229T3/es active Active
- 2010-09-29 WO PCT/US2010/050610 patent/WO2011041336A2/en active Application Filing
- 2010-09-29 CN CN201080054108.9A patent/CN102630229B/zh active Active
-
2012
- 2012-03-15 IL IL218662A patent/IL218662A0/en unknown
- 2012-03-16 ZA ZA2012/01984A patent/ZA201201984B/en unknown
- 2012-03-30 CL CL2012000800A patent/CL2012000800A1/es unknown
- 2012-04-09 CO CO12057624A patent/CO6531430A2/es not_active Application Discontinuation
- 2012-04-26 CR CR20120213A patent/CR20120213A/es unknown
- 2012-04-30 EC ECSP12011858 patent/ECSP12011858A/es unknown
- 2012-11-08 HK HK12111268.8A patent/HK1170505A1/xx unknown
-
2015
- 2015-01-23 JP JP2015011573A patent/JP2015145362A/ja not_active Withdrawn
-
2016
- 2016-07-13 JP JP2016138236A patent/JP2017014219A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2013506675A (ja) | 2013-02-28 |
CR20120213A (es) | 2012-07-09 |
RU2012117619A (ru) | 2013-11-10 |
US20120328608A1 (en) | 2012-12-27 |
ES2580229T3 (es) | 2016-08-22 |
WO2011041336A2 (en) | 2011-04-07 |
PE20120998A1 (es) | 2012-08-14 |
JP2015145362A (ja) | 2015-08-13 |
IL218662A0 (en) | 2012-05-31 |
ECSP12011858A (es) | 2012-06-29 |
MX342250B (es) | 2016-09-22 |
KR101782180B1 (ko) | 2017-10-23 |
HK1170505A1 (en) | 2013-03-01 |
ZA201201984B (en) | 2013-05-29 |
US9200071B2 (en) | 2015-12-01 |
JP2017014219A (ja) | 2017-01-19 |
CN102630229A (zh) | 2012-08-08 |
CL2012000800A1 (es) | 2012-08-31 |
EP2483311A2 (en) | 2012-08-08 |
CN102630229B (zh) | 2015-03-04 |
BR112012007252A2 (pt) | 2020-08-11 |
CA2775880A1 (en) | 2011-04-07 |
EP2483311B1 (en) | 2016-05-18 |
JP6025563B2 (ja) | 2016-11-16 |
CO6531430A2 (es) | 2012-09-28 |
MA33973B1 (fr) | 2013-02-01 |
AU2010300747A1 (en) | 2012-04-26 |
KR20120100952A (ko) | 2012-09-12 |
WO2011041336A3 (en) | 2012-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX342250B (es) | Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3. | |
EP2569434A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | |
IN2012DN02081A (es) | ||
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
WO2011037643A3 (en) | Compositions and methods for detecting and treating prostate carcinoma | |
MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX2010000465A (es) | Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores. | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
MX2012010434A (es) | Compuestos y composiciones novedosas para atacar a las celulas madre del cancer. | |
MX2009008510A (es) | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. | |
EA201270606A1 (ru) | Новое противоопухолевое применение кабазитаксела | |
MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
WO2010101793A3 (en) | Methods and compositions for the diagnosis, prognosis and treatment of cancer | |
MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
FR2945210B1 (fr) | Combinaison antitumorale comprenant l'ave8062 et le sorafenib | |
MX2010009697A (es) | Tratamientos anticancerigenos mejorados. | |
MX2011006532A (es) | Compuestos anticancerigenos. | |
WO2013070933A3 (en) | Compositions and methods for the treatment of prostate carcinoma | |
WO2010002454A3 (en) | Therapeutic combinations for use in neoplasia | |
TN2010000463A1 (en) | Compositions and methods for preparing and using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |